.Pharmacolibrary.Drugs.ATC.M.M05BX05 .Pharmacolibrary.Drugs.ATC.M.M05BX05| name: | Burosumab |
| ATC code: | M05BX05 | route: | subcutaneous |
| n-compartments | 1 |
Burosumab is a fully human monoclonal antibody targeting fibroblast growth factor 23 (FGF23). It is used for the treatment of X-linked hypophosphatemia (XLH) in adults and children 1 year of age and older. It is an approved drug for this indication in the US and EU.
Pharmacokinetic parameters reported for adult and pediatric patients with X-linked hypophosphatemia following subcutaneous administration. Based on population PK analysis.
Lee, SK, et al., & Shi, J (2022). Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked Hypophosphatemia. Journal of clinical pharmacology 62(1) 87–98. DOI:10.1002/jcph.1950 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34352114
Zhang, X, et al., & Carpenter, TO (2016). Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia. Journal of clinical pharmacology 56(4) 429–438. DOI:10.1002/jcph.611 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26247790